Charles Schwab Investment Management Inc. Acquires Shares of 156,784 Bicara Therapeutics Inc. (NASDAQ:BCAX)

Charles Schwab Investment Management Inc. bought a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 156,784 shares of the company's stock, valued at approximately $2,731,000. Charles Schwab Investment Management Inc. owned approximately 0.29% of Bicara Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also added to or reduced their stakes in BCAX. The Manufacturers Life Insurance Company acquired a new position in Bicara Therapeutics in the third quarter valued at about $582,000. FMR LLC acquired a new stake in Bicara Therapeutics in the 3rd quarter valued at $57,913,000. Walleye Capital LLC acquired a new position in Bicara Therapeutics during the third quarter valued at approximately $809,000. Vestal Point Capital LP acquired a new stake in shares of Bicara Therapeutics in the 3rd quarter valued at approximately $10,825,000. Finally, Braidwell LP acquired a new stake in Bicara Therapeutics in the third quarter valued at $42,219,000.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Wedbush reissued an "outperform" rating and set a $31.00 price target on shares of Bicara Therapeutics in a research report on Thursday. Cantor Fitzgerald reissued an "overweight" rating and set a $13.01 target price on shares of Bicara Therapeutics in a report on Thursday, March 13th. Finally, HC Wainwright raised their price target on Bicara Therapeutics from $42.00 to $45.00 and gave the company a "buy" rating in a report on Monday, January 27th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $36.50.

Remove Ads

Bicara Therapeutics Stock Performance

NASDAQ BCAX remained flat at $13.40 on Friday. The company's stock had a trading volume of 310,531 shares, compared to its average volume of 466,848. The stock's fifty day simple moving average is $13.04. Bicara Therapeutics Inc. has a 52-week low of $11.10 and a 52-week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.08). As a group, research analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.